JPRN-UMIN000025819已完成未知
Multicenter study to evaluate efficacy and safety of FINESIA system in dental implant treatment. - FINESIA Study
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University0 个研究点目标入组 40 人开始时间: 2017年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 70years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The exclusion criteria for study device. (1) Patients with hemorrhagic diathesis. (2) Patients with metabolic or endocrine diseases that may significantly affect postoperative bone formation (severe osteoporosis and others). (3) Patients taking steroids that may affect the postoperative healing of tissues. (4) Patients with uncontrolled diabetes. (5) Patients with strong bruxism or in overloading condition. (6) Patients known to be allergic to the metal (titanium alloy) used in this product. (7) Patients with a history of radiotherapy at the site of implantation. (8) Patients for whom postoperative care cannot be controlled such as the following: - Patients with dementia or other mental disabilities - Patients with drug addiction - Patients with alcoholism (9) Patients with excessive expectation for implant functions. (10) Patients with insufficient width and height of bone (bone mass) around the implant (patients who need combination therapy of bone prosthetic materials). (11) Patients with a history of impaired healing. (12) Patients with insufficient width of alveolar mucosa around the penetration site of the implant. (13) Patients with unstable adjacent abutment teeth. (14) Patients with serious cardiovascular disease such as myocardial infarction. (15) Pregnant or breast-feeding patients. (16) Other patients who are not adequate to participate this study. *Additionally, the exclusion criteria for clinical study.
研究者
相似试验
进行中(未招募)
2 期
Therapeutic drug development program for COVID-19JPRN-jRCTs051200049Iwahori Kota42
已完成
2 期
A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU)treatment resistant depression10027946NL-OMON55052COMPASS Pathfinder Ltd3
进行中(未招募)
1 期
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873EUCTR2020-001348-25-CZCOMPASS Pathfinder, Ltd150
进行中(未招募)
1 期
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialEUCTR2020-001348-25-PTCOMPASS Pathways, Ltd150
进行中(未招募)
1 期
ong Term Follow up study for subjects that participated in COMP001 and COMP003 trialTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873EUCTR2020-001348-25-NLCOMPASS Pathfinder, Ltd150
